Turning rare neurological disease biology into evidence for development.
BioSymetrics connects patient and registry data with computational discovery, disease modelling, and experimental validation to help partners define subgroups, prioritize biomarkers and targets, and explore therapeutic hypotheses in rare neurological disorders.
Rare disorders need better connected evidence.
Rare neurological disorders can be difficult to study because relevant data are fragmented across patient communities and registries. For partners planning trials or developing therapies, that fragmentation can make it harder to define meaningful subgroups, understand progression, and decide which biological signals warrant further study.
Build a clearer starting point for development.
We work with data from patients and registries to standardize datasets, define patient subgroups for clinical development, generate actionable insights, and activate cohorts that can support clinical trials for pharmaceutical and biotechnology partners. We build a structured foundation for translational research, clinical pathway design, and therapeutic programs.
A focused program for rare epilepsy.
CDKL5 deficiency disorder is a rare genetic neurodevelopmental and epileptic disorder associated with seizures that begin early in life and severe developmental impairment. In this funded translational program, we use our CRISPR/Cas9 cdkl5-deficient zebrafish models for high-throughput compound screening, then connect that work with human CDKL5 patient-derived brain organoids contributed by BrainStorm Therapeutics and complementary zebrafish models.
From one rare disorder to broader epilepsy biology.
Our KCC2 program uses chemical and genetic hypofunction models in zebrafish, automated behavioural analysis, and screening across multiple measures to assess seizure rescue, sedation, and nociception. Our work connects rare epilepsy mechanisms with a broader discovery process for hyperexcitability, target prioritization, and therapeutic development.
Create a clearer path from data to decisions.
We help partners turn structured cohorts and subgroup definitions into biomarker hypotheses, prioritized targets, and development packages that support partnering. These outputs can support trial preparation, translational research, clinical pathway design, and the next validation step across rare neurology programs.
Interested in building a clearer development path for a rare neurological disorder?
Bring a patient or registry dataset, a defined disorder, a candidate biomarker, or a therapeutic hypothesis. We can discuss cohort construction, subgroup definition, and the next validation study.
Partner with us